Geoff Meacham, an analyst from Citi, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target remains the same ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.26% of ...

Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage ...

Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...

A study using a Korean database found that COVID-19 infection raised long-term risks for various autoimmune and ...

Amgen Inc. may ultimately have to pay as much as $10.7 billion in taxes, interest and penalties to the IRS—nearly as much as ...

With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range.

Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Make America Healthy Again starts TOMORROW,” joked Donald Trump Jr. in a post on X sharing the picture. While it is hard to ...

Lilly's drug is the only oral treatment in a field of several injectable therapies being tested to treat high Lp(a), a risk factor for heart disease that affects one in five individuals globally ...

Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but ...